MX2017011838A - Composiciones y metodos para tratar carcinoma hepatocelular. - Google Patents

Composiciones y metodos para tratar carcinoma hepatocelular.

Info

Publication number
MX2017011838A
MX2017011838A MX2017011838A MX2017011838A MX2017011838A MX 2017011838 A MX2017011838 A MX 2017011838A MX 2017011838 A MX2017011838 A MX 2017011838A MX 2017011838 A MX2017011838 A MX 2017011838A MX 2017011838 A MX2017011838 A MX 2017011838A
Authority
MX
Mexico
Prior art keywords
methods
hepatocellular carcinoma
compositions
treating hepatocellular
treating
Prior art date
Application number
MX2017011838A
Other languages
English (en)
Inventor
Chen Zhi
Huang Sui
Lou Guohua
Green Richard
Wang Chen
Norton John
Liu Yanning
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Publication of MX2017011838A publication Critical patent/MX2017011838A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan en la presente composiciones y métodos para tratar, mejorar, o prevenir carcinoma hepatocelular en pacientes. En particular, la invención se refiere a métodos para tratar, mejorar, o prevenir carcinoma hepatocelular en un paciente, que comprende la administración al paciente de 6-metoxietilamino-numon afida sola o en combinación con sorafenib.
MX2017011838A 2015-03-19 2016-03-18 Composiciones y metodos para tratar carcinoma hepatocelular. MX2017011838A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562135435P 2015-03-19 2015-03-19
PCT/US2016/023212 WO2016149647A1 (en) 2015-03-19 2016-03-18 Compositions and methods for treating hepatocellular carcinoma

Publications (1)

Publication Number Publication Date
MX2017011838A true MX2017011838A (es) 2018-06-06

Family

ID=56919582

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011838A MX2017011838A (es) 2015-03-19 2016-03-18 Composiciones y metodos para tratar carcinoma hepatocelular.

Country Status (7)

Country Link
US (2) US20180110743A1 (es)
EP (1) EP3270919A4 (es)
JP (1) JP2018508546A (es)
AU (1) AU2016232775A1 (es)
CA (1) CA2979843A1 (es)
MX (1) MX2017011838A (es)
WO (1) WO2016149647A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5341081B2 (ja) * 2007-07-25 2013-11-13 アルマ マーテル ステューディオラム − ウニヴェルスィタ ディ ボローニャ 肝細胞癌処置用医薬組成物および医薬キット
JP6205373B2 (ja) * 2012-02-03 2017-09-27 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｎｄｇａ誘導体およびソラフェニブを含む組成物、ならびにがんの処置におけるこれらの使用
CN104257655B (zh) * 2014-08-31 2016-06-22 浙江大学 化合物mean在制备抑制hcv复制的药物中的用途

Also Published As

Publication number Publication date
JP2018508546A (ja) 2018-03-29
AU2016232775A1 (en) 2017-10-12
US20190374485A1 (en) 2019-12-12
CA2979843A1 (en) 2016-09-22
EP3270919A1 (en) 2018-01-24
WO2016149647A1 (en) 2016-09-22
US20180110743A1 (en) 2018-04-26
EP3270919A4 (en) 2018-10-24

Similar Documents

Publication Publication Date Title
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
MY187540A (en) Compounds active towards bromodomains
WO2019006005A3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX370792B (es) Composiciones para usarse en el tratamiento de cáncer.
MX2017005134A (es) Tratamiento del cáncer con inmunoestimuladores.
MX2017015012A (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
PH12016502352A1 (en) Pharmaceutical composition
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
TW201613578A (en) Pharmaceutical combinations
MX2017002489A (es) Agentes terapeuticos humanos.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
MX2017004723A (es) Composicion farmaceutica para usarse en el tratamiento o la prevencion de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugia de derivacion gastrica.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MX2018004532A (es) Combinacion de trazodona y gabapentina para el tratamiento de dolor.
MX2017011838A (es) Composiciones y metodos para tratar carcinoma hepatocelular.
MX2016001177A (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
MX2017014463A (es) Cabazitaxel y su uso para tratar cancer.